Patents by Inventor Chung-Wai Shiau

Chung-Wai Shiau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10800732
    Abstract: Disclosed are a series of malonamide derivatives having a chemical structure(I), their synthesis, and evaluation of their bioactivities against bacterial cell, bacterial-infected C. elegans and mice.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: October 13, 2020
    Assignees: NATIONAL TAIWAN UNIVERSITY, NATIONAL YANG-MING UNIVERSITY
    Inventors: Chung-Wai Shiau, Hao-Chieh Chiu
  • Patent number: 10793527
    Abstract: The present invention discloses a compound of the formula (I), which acts as an agonist of adenosine monophosphate-activated protein kinase, which induce phosphorylation and activation of AMPK?, thereby further regulating downstream signaling pathways, inhibiting growth and proliferation of liver cancer cells and breast cancer cells, and also inducing apoptosis of adipocytes. Therefore, the compound provided by the present invention can be utilised for treatment and preparation of pharmaceutical composition for cancer, and lipid metabolism-related diseases or syndromes mediated by AMPK.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: October 6, 2020
    Assignee: NATIONAL YANG-MING UNIVERSITY
    Inventors: Chung-Wai Shiau, Jung-Chen Su, Yan-Ju Lin, Jui-Wen Huang
  • Patent number: 10745346
    Abstract: Some novel compounds are provided in this disclosure. These novel compounds have potential SHP-1 agonist activity for being used in treating cancer.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: August 18, 2020
    Inventors: Kuen-Feng Chen, Chung-Wai Shiau
  • Publication number: 20200016100
    Abstract: The present invention provides an application of 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[3-(4-cyanophenoxy)phenyl]urea in preparation of drugs for treating and reducing a fibrotic disease. The fibrotic disease is skin sclerosis, cardiac fibrosis, pulmonary fibrosis, hepatic fibrosis, pancreatic fibrosis, or renal fibrosis.
    Type: Application
    Filed: September 22, 2017
    Publication date: January 16, 2020
    Inventors: Kuen-Feng CHEN, Chung-Wai SHIAU
  • Publication number: 20190194142
    Abstract: The present invention discloses a compound of the formula (I), which acts as an agonist of adenosine monophosphate-activated protein kinase, which induce phosphorylation and activation of AMPK?, thereby further regulating downstream signaling pathways, inhibiting growth and proliferation of liver cancer cells and breast cancer cells, and also inducing apoptosis of adipocytes. Therefore, the compound provided by the present invention can be utilised for treatment and preparation of pharmaceutical composition for cancer, and lipid metabolism-related diseases or syndromes mediated by AMPK.
    Type: Application
    Filed: September 6, 2017
    Publication date: June 27, 2019
    Inventors: Chung-Wai SHIAU, Jung-Chen SU, Yan-Ju LIN, Jui-Wen HUANG
  • Patent number: 10189795
    Abstract: The present invention provides new compounds of formula I(a)-I(d) and II, The compounds can inhibit cancerous inhibitor of protein phosphate 2A (CIP2A), can be used as protein phosphate 2A (PP2A) accelerator and oncoprotein SET antagonist, and can treat cancers effectively.
    Type: Grant
    Filed: July 7, 2015
    Date of Patent: January 29, 2019
    Inventors: Kuen-Feng Chen, Chung-Wai Shiau
  • Publication number: 20180237379
    Abstract: Disclosed are a series of malonamide derivatives having a chemical structure(I), their synthesis, and evaluation of their bioactivities against bacterial cell, bacterial-infected C.elegans and mice.
    Type: Application
    Filed: August 12, 2016
    Publication date: August 23, 2018
    Applicant: National Taiwan University
    Inventors: Chung-Wai Shiau, Hao-Chieh Chiu
  • Publication number: 20180237385
    Abstract: Some novel compounds are provided in this disclosure. These novel compounds have potential SHP-1 agonist activity for being used in treating cancer.
    Type: Application
    Filed: August 31, 2016
    Publication date: August 23, 2018
    Inventors: KUEN-FENG CHEN, CHUNG-WAI SHIAU
  • Publication number: 20170204071
    Abstract: The present invention provides new compounds of formula I(a)-I(d) and II, The compounds can inhibit cancerous inhibitor of protein phosphate 2A (CIP2A), can be used as protein phosphate 2A (PP2A) accelerator and oncoprotein SET antagonist, and can treat cancers effectively.
    Type: Application
    Filed: July 7, 2015
    Publication date: July 20, 2017
    Inventors: KUEN-FENG CHEN, CHUNG-WAI SHIAU
  • Patent number: 9394261
    Abstract: A series of mono- and di-substituted quinazoline and pyrimidine derivatives based on the skeleton of erlotinib (an EGFR inhibitor) were synthesized and their bioactivities against hepatocellular carcinoma and human lung adenocarcinoma were evaluated.
    Type: Grant
    Filed: February 25, 2015
    Date of Patent: July 19, 2016
    Assignees: NATIONAL YANG-MING UNIVERSITY, NATIONAL TAIWAN UNIVERSITY
    Inventors: Chung-Wai Shiau, Kuen-Feng Chen
  • Patent number: 9216950
    Abstract: The present invention provides new compounds of formula I, II or III, which have Src homology-2 containing protein tyrosine phosphatase-1 (SHP-1) agonist activity. Also provided are treatment methods using the compounds of formula I, II or III.
    Type: Grant
    Filed: August 3, 2012
    Date of Patent: December 22, 2015
    Assignees: NATIONAL TAIWAN UNIVERSITY, NATIONAL YANG-MING UNIVERSITY, DCB-USA LLC
    Inventors: Chung-Wai Shiau, Kuen-Feng Chen
  • Publication number: 20150246891
    Abstract: A series of mono- and di-substituted quinazoline and pyrimidine derivatives based on the skeleton of erlotinib (an EGFR inhibitor) were synthesized and their bioactivities against hepatocellular carcinoma and human lung adenocarcinoma were evaluated.
    Type: Application
    Filed: February 25, 2015
    Publication date: September 3, 2015
    Inventors: Chung-Wai SHIAU, Kuen-Feng CHEN
  • Patent number: 9090617
    Abstract: The present invention provides new compounds of formula I, II or III, which have Src homology-2 containing protein tyrosine phosphatase-1 (SHP-1) agonist activity. Also provided are treatment methods using the compounds of formula I, II or III.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: July 28, 2015
    Assignees: NATIONAL TAIWAN UNIVERSITY, NATIONAL YANG-MING UNIVERSITY, DCB-USA LLC
    Inventors: Chung-Wai Shiau, Kuen-Feng Chen
  • Publication number: 20150191467
    Abstract: The present invention provides new compounds of formula I, II or III, which have Src homology-2 containing protein tyrosine phosphatase-1 (SHP-1) agonist activity. Also provided are treatment methods using the compounds of formula I, II or III.
    Type: Application
    Filed: March 23, 2015
    Publication date: July 9, 2015
    Inventors: Chung-Wai SHIAU, Kuen-Feng CHEN
  • Publication number: 20140200239
    Abstract: The present invention provides new compounds of formula I, II or III, which have Src homology-2 containing protein tyrosine phosphatase-1 (SHP-1) agonist activity. Also provided are treatment methods using the compounds of formula I, II or III.
    Type: Application
    Filed: August 3, 2012
    Publication date: July 17, 2014
    Applicant: National Taiwan University
    Inventors: Chung-Wai Shiau, Kuen-Feng Chen
  • Publication number: 20140148482
    Abstract: The present application provides a method for screening compounds for cancer treatment comprising treating cancer cells with a candidate compound for sufficient time for detectable expression of a gene selected from GADD45 family; and detecting the level of expression of the gene as compared to the level of expression in the absence of the candidate compound; wherein an increased level of expression in the presence of the candidate compound as compared to expression in the absence of the candidate compound indicates that the candidate compound acts as an inhibitor of the cancer cells. In some embodiments, the method can be used for screening compounds for treatment of sorafenib-resistant hepatocellular carcinoma. The present application further provides a method for treating hepatocellular carcinoma comprising administering to a subject having hepatocellular carcinoma a therapeutic effective amount of an agonist of GADD45 family.
    Type: Application
    Filed: November 14, 2013
    Publication date: May 29, 2014
    Applicant: National Taiwan University
    Inventors: Da-Liang Ou, Chung-Wai Shiau, Chiun Hsu
  • Publication number: 20140080848
    Abstract: A series of mono- and di-substituted quinazoline and pyrimidine derivatives based on the skeleton of erlotinib (an EGFR inhibitor) were synthesized and their bioactivities against hepatocellular carcinoma and human lung adenocarcinoma were evaluated.
    Type: Application
    Filed: September 13, 2013
    Publication date: March 20, 2014
    Applicants: National Taiwan University, National Yang-Ming University
    Inventors: Chung-Wai SHIAU, Kuen-Feng CHEN
  • Patent number: 8309582
    Abstract: Bcl-xL/Bcl-2 binding inhibitors useful in the treatment of unwanted proliferating cells, including cancers and precancers, in subjects in need of such treatment. Also provided are methods of treating a subject having unwanted proliferating cells comprising administering a therapeutically effective amount of a Bcl-xL/Bcl-2 binding inhibitor described herein to a subject in need of such treatment. Also provided are methods of preventing the proliferation of unwanted proliferating cells, such as cancers and precancers, in a subject comprising the step of administering a therapeutically effective amount of a Bcl-xL/Bcl-2 binding inhibitor described herein to a subject at risk of developing a condition characterized by unwanted proliferating cells.
    Type: Grant
    Filed: January 5, 2010
    Date of Patent: November 13, 2012
    Assignee: The Ohio State University Research Foundation
    Inventors: Ching-Shih Chen, Chung-Wai Shiau
  • Publication number: 20100168184
    Abstract: Bcl-xL/Bcl-2 binding inhibitors useful in the treatment of unwanted proliferating cells, including cancers and precancers, in subjects in need of such treatment. Also provided are methods of treating a subject having unwanted proliferating cells comprising administering a therapeutically effective amount of a Bcl-xL/Bcl-2 binding inhibitor described herein to a subject in need of such treatment. Also provided are methods of preventing the proliferation of unwanted proliferating cells, such as cancers and precancers, in a subject comprising the step of administering a therapeutically effective amount of a Bcl-xL/Bcl-2 binding inhibitor described herein to a subject at risk of developing a condition characterized by unwanted proliferating cells.
    Type: Application
    Filed: January 5, 2010
    Publication date: July 1, 2010
    Inventors: Ching-Shih Chen, Chung-Wai Shiau
  • Patent number: 7714005
    Abstract: Bcl-xL/Bcl-2 binding inhibitors useful in the treatment of unwanted proliferating cells, including cancers and precancers, in subjects in need of such treatment. Also provided are methods of treating a subject having unwanted proliferating cells comprising administering a therapeutically effective amount of a Bcl-xL/Bcl-2 binding inhibitor described herein to a subject in need of such treatment. Also provided are methods of preventing the proliferation of unwanted proliferating cells, such as cancers and precancers, in a subject comprising the step of administering a therapeutically effective amount of a Bcl-xL/Bcl-2 binding inhibitor described herein to a subject at risk of developing a condition characterized by unwanted proliferating cells.
    Type: Grant
    Filed: December 22, 2005
    Date of Patent: May 11, 2010
    Assignee: The Ohio State University Research Foundation
    Inventors: Ching-Shih Chen, Chung-Wai Shiau